Takeda Pharmaceutical Co Ltd - FY2022 Financial Summary
Business Context and Reporting Period
This Form 6-K filing, dated May 11, 2022, summarizes the consolidated financial results for Takeda Pharmaceutical Company Limited for the fiscal year ended March 31, 2022 (FY2022). Takeda is a global biopharmaceutical company focused on Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology. The company operates in approximately 80 countries and reports under International Financial Reporting Standards (IFRS).
Key Financial Metrics
| Metric | FY2022 (Billion JPY) | FY2021 (Billion JPY) | Change (%) |
|---|---|---|---|
| Revenue | 3,569.0 | 3,197.8 | +11.6% |
| Operating Profit | 460.8 | 509.3 | -9.5% |
| Profit Before Tax | 302.6 | 366.2 | -17.4% |
| Net Profit (Attributable to Owners) | 230.1 | 376.0 | -38.8% |
| Basic EPS (JPY) | 147.14 | 240.72 | -38.9% |
| Core Operating Profit | 955.2 | 967.9 | -1.3% |
| Core EPS (JPY) | 425 | 420 | +1.2% |
Liquidity, Debt, and Cash Flow
- Cash Flow: Net cash from operating activities was 1,123.1 billion JPY, an increase of 11.2% from the prior year. Net cash used in investing activities was 198.1 billion JPY, and net cash used in financing activities was 1,070.3 billion JPY.
- Cash Position: Cash and cash equivalents at year-end were 849.7 billion JPY, a decrease of 116.5 billion JPY from the prior year.
- Debt: Total Bonds and Loans decreased by 290.0 billion JPY to 4,345.4 billion JPY. This reduction was driven by significant debt repayments, including the prepayment of the Japan Bank for International Cooperation (JBIC) loan and redemption of various senior notes.
- Equity: Total equity attributable to owners of the company increased to 5,683.0 billion JPY, primarily due to currency translation adjustments offset by share buybacks and dividends.
Material Changes and Drivers
- Revenue Growth: Reported revenue grew 11.6%, driven by a 133.0 billion JPY one-time gain from the sale of a diabetes portfolio in Japan (4.2 percentage points) and favorable foreign exchange rates. Excluding these factors, underlying revenue growth was 7.4%.
- Profit Decline: Net profit dropped 38.8% primarily due to a 65.4 billion JPY tax charge related to an Irish tax assessment on a break fee from a terminated 2014 acquisition offer, and a 15.4 billion JPY share of loss from equity method investments. Operating profit declined 9.5% due to increased R&D expenses and amortization/impairment charges.
- Therapeutic Area Performance:
- Gastroenterology: Revenue increased 12.6%, led by ENTYVIO (+21.5%) and TAKECAB (+20.7%).
- PDT Immunology: Revenue increased 20.6%, driven by strong demand for immunoglobulin products and albumin.
- Neuroscience: Revenue increased 15.6%, driven by VYVANSE/ELVANSE (+20.4%).
- Rare Diseases: Revenue increased 3.3%, though Rare Hematology declined 2.1% due to competition.
- Divestitures: The company completed the sale of its diabetes portfolio in Japan and various non-core consumer healthcare assets, which impacted comparability with the prior year.
Guidance, Outlook, and Risks
- FY2023 Forecast: Takeda forecasts revenue of 3,690.0 billion JPY (+3.4%), operating profit of 520.0 billion JPY (+12.8%), and net profit of 292.0 billion JPY (+26.9%). Core EPS is forecast at 484 JPY (+14.0%).
- Management Guidance: The company now provides guidance based on "Core Growth at Constant Exchange Rate" (CER). It expects low-single-digit Core Revenue growth, high-single-digit Core Operating Profit growth, and high-single-digit Core EPS growth for FY2023.
- Capital Allocation: Takeda targets a net debt-to-adjusted EBITDA ratio of "low-twos" (approx. 2x) by FY2024. It maintains a dividend policy of 180 JPY per share annually and continues share buybacks.
- Risks and Contingencies:
- Geopolitical: Operations in Russia and Ukraine represent 1.7% of revenue. Takeda has suspended non-essential activities in Russia but continues to supply patients. No material financial impact was recorded in FY2022.
- COVID-19: While the pandemic did not materially impact FY2022 results, the Omicron variant caused temporary disruptions in shipping and diagnostic procedures. The company expects approximately 50.0 billion JPY in revenue from COVID-19 vaccines in FY2023.
- Patent Expirations: The company anticipates revenue declines from the loss of exclusivity for VELCADE in the U.S., which is expected to be offset by growth in other products.
Investor Verification Checklist
- Verify the impact of the 65.4 billion JPY Irish tax charge on the effective tax rate and future cash tax obligations.
- Confirm the sustainability of the 7.4% underlying revenue growth excluding one-time divestiture gains and FX effects.
- Monitor the execution of the debt reduction plan to achieve the "low-twos" net debt/EBITDA target by FY2024.
- Assess the commercial performance of new launches (LIVTENCITY, EXKIVITY) and the impact of VELCADE patent loss in the U.S.
- Review the reconciliation of non-IFRS "Core" and "Underlying" metrics to IFRS reported figures in the appendices.